Bridging Molecules and Models: A Study of Curcumin-Eugenol Anti-Inflammatory Synergy

Inflammation, a fundamental biological response to harmful stimuli like damaged cells or irritants, is a crucial component of the body’s innate immune defense. It initiates healing and tissue repair. While acute inflammation is a self-limiting and protective mechanism, chronic inflammation has been linked to the pathogenesis of various ailments, such as cardiovascular disease, rheumatoid arthritis, diabetes, inflammatory bowel disease, and neurodegenerative disorders. The inflammatory response requires a cascade of biochemical events triggered by the immune system. These include the release of cytokines, chemokines, prostaglandins, and reactive oxygen species (ROS), which collectively contribute to the clinical symptoms of inflammation— heat, swelling, pain, redness and loss of function. The cellular participants of inflammation, such as neutrophils, lymphocytes and macrophages are recruited to the site of injury to neutralize the offending agent and promote recovery. ^[1] Despite the essential nature of inflammation in host defense, persistent or uncontrolled inflammation is harmful and contributes to the occurence of chronic diseases. This has prompted the search for therapeutic agents that can modulate the inflammatory process without eliciting severe side effects. Widely used anti-inflammatory treatments like NSAIDs, steroids, and biologics offer symptomatic relief, but their prolonged use is linked to adverse effects. However, their long-term use is correlated with a wide variety of negative consequences such as gastrointestinal toxicity, cardiovascular obstacles, immunosuppression and increased susceptibility to infections. ^[2] NSAIDs, for instance, suppress cyclooxygenase enzymes (COX-1 and COX-2), this consequence to reduced prostaglandin synthesis but also compromises gastric mucosal protection and renal function. Corticosteroids act broadly on inflammatory gene expression but may cause metabolic disturbances, osteoporosis, and adrenal suppression when used chronically. Biologic agents, though highly effective, are often expensive and may result in immune suppression. Given these challenges, there is growing interest in exploring natural anti-inflammatory agents derived from plants that are effective, affordable, and possess fewer side effects. ^[3] A polyphenolic compound termed curcumin is extracted from the rhizome of Curcuma longa, or turmeric. It has been extensively researched for its anti-inflammatory properties, anticancer, antioxidant, and neuroprotective properties. Mechanistically, curcumin modulates several signaling pathways, including JAK/STAT, NF-κB, and MAPK, thereby inhibiting the expression of inflammatory mediators as inducible nitric oxide synthase (iNOS), COX-2, IL-6, and TNF-α. ^[4] Eugenol is a phenolic substance primarily extracted from clove oil (Syzygium aromaticum). It has proven to have an analgesic, antioxidant, anti-inflammatory and antimicrobial activities. Eugenol is known to inhibit prostaglandin synthesis, reduce leukocyte migration, and modulate ion channels and receptor-mediated pathways, including NMDA and histamine receptors, which play a vital role in inflammation and pain perception. ^[5] Both curcumin and eugenol possess membrane-stabilizing properties and free radical scavenging abilities, making them ideal candidates for the development of novel anti-inflammatory therapies. Importantly, they are both generally regarded as safe (GRAS) substances and have been employed by traditional medicine over decades.  While curcumin and eugenol have been studied extensively in isolation, there is limited evidence evaluating their combined effects. Recent findings suggest that eugenol may enhance the bioavailability of curcumin by improving membrane permeability and inhibiting its metabolic degradation. This synergistic interaction could potentiate their anti-inflammatory efficacy by targeting multiple mechanisoms contribited in the inflammatory reaction. The combined administration of curcumin and eugenol may offer several advantages: reduced required dosage of each compound, enhanced therapeutic efficacy, minimized side effects, and a broader spectrum of action. Such combinations are particularly relevant in the context of chronic inflammatory diseases where long-term management is necessary. ^[6] The present research aims to evaluate the anti-inflammatory synergy of curcumin and eugenol using in vitro models such as protein denaturation assays and in silico molecular docking studies. These approaches aim to elucidate molecular interactions and medicinal benfits of this phytochemical combination.

Fig:1.2 Syzygium romaticum (Eugenol)

2.1 Thin-Layer Chromatography (TLC) of Curcumin and Eugenol 

TLC was performed using silica gel pre-coated plates as the stationary phase, activated by heating at 110°C for 30 minutes to enhance adsorption. A baseline was marked 1 cm from the bottom for consistent sample application and accurate Rf measurement. Sample solutions, including curcumin and eugenol extracts (10 mg/mL in ethanol) and standard solutions (curcumin in methanol, eugenol in ethanol at 0.5 mg/mL), were applied in 1–2 µL volumes using capillary tubes. After solvent evaporation, plates were placed in pre-saturated chambers with mobile phases for development: n-hexane and ethyl acetate (7:3) for curcumin, and hexane-acetone (9:3) for eugenol. The solvent ascended to three to fourths of the plate’s height, followed by drying and visualization under UV light at 254 nm and 365 nm. Curcumin appeared as a yellow fluorescent spot, while eugenol displayed dark spots, ensuring reliable phytochemical analysis. ^[7]

2.2 In vitro evaluation of anti-inflammatory activity.

The in vitro evaluation of anti-inflammatory activity of curcumin and eugenol was done by protein denaturation method (albumin method) and anti-proteinase method.

2.2.1 In vitro protein denaturation method.

 The in vitro protein denaturation method, often referred to as the albumin method, was employed to assess their ability to inhibit protein denaturation, a signature of inflammation. This method was carried out for three primary test samples: Curcumin, Eugenol, and a fixed combination containing both Curcumin and Eugenol in equal proportions. For comparative purposes and to establish a standard reference, Indomethacin, a familiar non-steroidal anti-inflammatory drug (NSAID), was utilized as the standard control. ^[8]

2.2.2 In vitro Anti-Proteinase Action 

To elucidate the anti-inflammatory mechanisms of the selected compounds, an in vitro anti-proteinase action assay was conducted. This assay investigated the ability of the test samples to inhibit the activity of proteinases, enzymes that degrade connective tissue and produce inflammatory mediators. Similar to the protein denaturation method, Curcumin, Eugenol, and a combination of Curcumin and Eugenol (in equal proportions) were evaluated. The most prevalent reference substance employed for direct comparison was indomethacin. ^[9] The assay involved preparing a reaction mixture with a proteinase, a substrate, and varying concentrations of the test compounds and the standard. The enzymatic cleavage of the substrate was measured, typically through the liberation of a chromogenic product that could be quantified spectrophotometrically. An anti-proteinase agent inhibited this activity, reducing the measured product. The percentage inhibition of proteinase activity was determined for each concentration. This assay helps understand how Curcumin, Eugenol, and their combination might mitigate inflammation by preventing tissue breakdown and reducing inflammatory peptide generation. The data contribute to a comprehensive understanding of their in vitro anti-inflammatory profile.

2.3 Molecular Docking Studies

Molecular docking is a computer technique that predicts the intensity of a contact, typically represented as a docking score or binding affinity (Glide score in this work), as well as the preferred orientation of a molecule (ligand) when coupled to a target protein (receptor). This method is essential to contemporary drug discovery since it clarifies possible molecular pathways prior to the costly and drawn-out in vivo studies. In this study, we selected four key protein targets involved in inflammation:

• Cyclooxygenase-2 (COX-2) – a key enzyme in prostaglandin biosynthesis and a well-established target of NSAIDs.
• Janus kinase (JAK) – involved in cytokine receptor signaling and immune modulation.
• Nuclear Factor kappa B (NF-κB) – a central transcription factor regulating expression of pro-inflammatory cytokines.
• Signal Transducer and Activator of Transcription 3 (STAT3) – another transcription factor involved in inflammation and immune response.

The Glide scores (expressed in negative kcal/mol) indicate the binding strength—the more negative the score, the stronger and more favorable the binding.

RESULTS

3.1 Thin-Layer Chromatography (TLC) of Curcumin, and Eugenol

Thin layer chromatography of Curcumin and Eugenol was performed.